European Archives - Page 1193 of 1345 - European Medical Journal

EMJ

Cell Diversity in Barrett’s Oesophagus Patients Good Predictor of Cancer Risk

The genetic diversity measured between the cells affected by Barrett’s oesophagus has been found to be a good predictor of which patients are at a high…

EMJ

Nanotechnology Applied to Ginger Offers Novel Treatment for Bowel Disease

NANOPARTICLES derived from ginger have been used to produce a beneficial effect in the treatment of inflammatory bowel disease (IBD), offering a novel…

EFIC Symposium: New Therapeutic Strategies to Combat Joint Pain

Dubrovnik, September 23, 2016 – Joint pain continues to be one of the main reasons for persisting disablement. One explanation, among others, is that…

EFIC Symposium: Chronic Pain Following Joint Surgery – Experts Call for New Approaches

Dubrovnik, September 22, 2016 – Many patients are disappointed and dissatisfied when they find they are still experiencing pain in the months and years…

EFIC Symposium: Myths and Facts About Joint Pain

Dubrovnik, September 21, 2016 – A lot of incorrect assumptions about joint pain are in circulation. “The sometimes overly pessimistic misconceptions can…

Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress

Germany, September 12, 2016 – Merck, a leading science and technology company, today announced key symposia and more than 30 presentations of clinical…

Janssen Receives CHMP Positive Opinion for STELARA® (Ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Crohn’s Disease in the European Union

Belgium, September 16, 2016 – Janssen-Cilag International NV (“Janssen”) announced today that the Committee for Medicinal Products for Human Use (CHMP)…

EMJ

Scientists Mobilise Nanorobots to Fight Against Cancer

SWARMS of magneto-aerotactic bacteria equipped with covalently-bound drug-containing nanoliposomes have been administered into the bloodstream to…

EMJ

CRISPR Genome Editing Allows Blood Cells to Resist Sickle Cell Disease

INNOVATIVE CRISPR genome editing has been used to inhibit the pathological morphology of red blood cells caused by sickle cell disease, offering a new…

Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform

To accelerate the overarching mission to make diabetes management easier, Glooko and Diasend announced to be merged into a unified company.